Profile data is unavailable for this security.
About the company
Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. It operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.
- Revenue in CAD (TTM)1.00m
- Net income in CAD-4.35m
- Incorporated1989
- Employees0.00
- LocationTheralase Technologies Inc41 Hollinger RoadTORONTO M4B 3G4CanadaCAN
- Phone+1 (416) 699-5273
- Fax+1 (416) 699-5250
- Websitehttps://theralase.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conavi Medical Corp | 9.12m | -20.52m | 41.50m | 4.00 | -- | -- | -- | 4.55 | -0.386 | -0.386 | 0.1586 | -0.2349 | 1.08 | -- | -- | -- | -243.23 | -- | -613.64 | -- | 83.61 | -- | -224.91 | -- | 0.9655 | -1.23 | 10.61 | -- | -- | -- | -- | -- | -- | -- |
| Covalon Technologies Ltd | 32.82m | 2.06m | 45.70m | -- | 22.68 | 1.49 | 15.17 | 1.39 | 0.0736 | 0.0736 | 1.18 | 1.12 | 0.9662 | 2.03 | 6.92 | -- | 6.06 | -5.25 | 6.84 | -6.53 | 53.24 | 52.97 | 6.27 | -6.68 | 6.40 | -- | 0.0683 | -- | 5.29 | 19.43 | -22.91 | -- | 32.67 | -- |
| Sernova Biotherapeutics Inc | 0.00 | -15.74m | 48.38m | 8.00 | -- | -- | -- | -- | -0.048 | -0.048 | 0.00 | -0.0753 | 0.00 | -- | -- | 0.00 | -379.75 | -102.72 | -- | -177.86 | -- | -- | -- | -- | -- | -19.61 | -- | -- | -- | -- | 51.10 | -- | -- | -- |
| Medmira Inc | 233.00k | -4.04m | 48.84m | 65.00 | -- | -- | -- | 209.61 | -0.0058 | -0.0058 | 0.0003 | -0.0333 | 0.0543 | 0.3625 | 0.1737 | -- | -94.02 | -62.12 | -- | -- | 69.69 | 65.17 | -1,732.61 | -311.65 | 0.0565 | -2.96 | -- | -- | -41.70 | -23.52 | -36.02 | -- | -- | -- |
| Theralase Technologies Inc | 1.00m | -4.35m | 78.40m | 0.00 | -- | 71.75 | -- | 78.32 | -0.0174 | -0.0174 | 0.004 | 0.0043 | 0.3215 | 0.8203 | 1.39 | -- | -139.83 | -73.48 | -244.27 | -85.81 | 55.34 | 46.93 | -434.88 | -486.10 | 0.5668 | -- | 0.2264 | -- | -3.45 | 1.40 | 6.89 | -- | -48.16 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Kohmann Bosshard Financial Services LLCas of 31 Dec 2025 | 2.50k | 0.00% |
